Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

Grazyna Stasiak, PhD, Malgorzata Zajac, PhD, Joanna Zaleska, Michal Kielbus, PhD, Jakub Czapinski, Andrzej Stepulak, MD PhD, Olga Jankowska-Lecka, PhD, Tomasz Gromek, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Bozena Sokolowska, MD PhD, Marek Hus, MD PhD, Lars Bullinger, MD PhD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 2878.

https://doi.org/10.1182/blood.V128.22.2878.2878

Published: 2016

Journal Articles

The Oligodendrocyte Lineage Transcription Factor 2 (OLIG2) Is Epigenetically Regulated in AML and Suppresses Leukemia Cell Growth

Arzu Yalcin, PhD, Marlon Kovarbasic, Mahmoud Abdelkarim, Gregor Klaus, Julius Wehrle, MD, Verena I. Gaidzik, MD, Heike L Pahl, PhD, Konstanze Doehner, MD, Lars Bullinger, MD PhD, Michael Lübbert, Björn Hackanson, MD

Blood (2014) 124 (21): 3540.

https://doi.org/10.1182/blood.V124.21.3540.3540

Published: 2014

Journal Articles

ABCB1 Expression in Acute Myeloid Leukemia (AML): A Possible Predictive Value for Treatment Resistance?

Stephany Corrêa, PhD, Eliana Abdelhay, PhD, Peter Paschka, MD, Verena I. Gaidzik, MD, Rocio Hassan, PhD, Rainer Claus, MD, Richard F. Schlenk, MD, Konstanze Döhner, MD, Lars Bullinger, MD PhD

Blood (2014) 124 (21): 3618.

https://doi.org/10.1182/blood.V124.21.3618.3618

Published: 2014

Journal Articles

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Vanessa Schneider, Lu Zhang, Markus Rojewski, Lars Bullinger, MD PhD, Susanne Hofmann, MD, Marlies Goetz, Konstanze Doehner, MD, Hartmut Doehner, Prof., Christian Buske, MD, Jochen Greiner, MD

Blood (2014) 124 (21): 5783.

https://doi.org/10.1182/blood.V124.21.5783.5783

Published: 2014

Journal Articles

Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories

Blood (2014) 124 (21): 2374.

https://doi.org/10.1182/blood.V124.21.2374.2374

Published: 2014

Journal Articles

Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)

Claudia Bruedigam, Frederik Otzen Bagger, Florian H Heidel, MD, Catherine Kuhn, Solene Guignes, Axia Song, Rebecca Austin, Therese Vu, Erwin M Lee, PhD, Andrew S. Moore, MBBS, FRACP, PhD, Richard B. Lock, PhD, Lars Bullinger, MD PhD, Geoff R Hill, MD, Steven W Lane, MD PhD

Blood (2014) 124 (21): 2322.

https://doi.org/10.1182/blood.V124.21.2322.2322

Published: 2014

Journal Articles

Constitutive gp130-JAK-STAT3 Signaling Induces a Plasma Cell Disorder Representing Genetic and Clinical Features of Human Myeloma – a Novel in Vivo Model for the Patient Subgroup Characterized By a STAT3 Target Gene Signature

Sabine Steidle, MD, Tobias Dechow, MD, Katharina Götze, Martina Rudelius, MD, Konstanze Pechloff, PhD, Kerstin Behnke, Lars Bullinger, MD PhD, Falko Fend, MD, Soberon Valeria, PhDstudent, Marc Schmidt-Supprian, PhD, Florian Bassermann, MD, Jürgen Ruland, MD, Christian Peschel, MD, Ulrich Keller, MD

Blood (2014) 124 (21): 648.

https://doi.org/10.1182/blood.V124.21.648.648

Published: 2014

Journal Articles

Lenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q)

Emma C. Fink, Jan Krönke, MD, Slater N. Hurst, Namrata D. Udeshi, PhD, Tanya Svinkina, Rebekka K. Schneider, MD, Marie E. McConkey, PhD, Marcus Järås, PhD, Lars Bullinger, MD PhD, Steven A. Carr, PhD, Benjamin L. Ebert, MD DPhil

Blood (2014) 124 (21): 4.

https://doi.org/10.1182/blood.V124.21.4.4

Published: 2014

Journal Articles

Decitabine Response Associated Gene Expression Patterns In Acute Myeloid Leukemia (AML)

Stephan R Bohl, MD, Rainer Claus, MD, Anna Dolnik, Richard F. Schlenk, MD, Konstanze Döhner, MD, Björn Hackanson, MD, Hartmut Döhner, MD, Michael Lübbert, MD, Lars Bullinger, MD, PhD

Blood (2013) 122 (21): 3756.

https://doi.org/10.1182/blood.V122.21.3756.3756

Published: 2013

Journal Articles

Differential DNA Methylation Predicts Response To Combined Treatment Regimens With a DNA Methyltransferase Inhibitor In Acute Myeloid Leukemia (AML)

Maximilian Schmutz, Manuela Zucknick, PhD, Richard F. Schlenk, MD, Konstanze Döhner, MD, Hartmut Döhner, MD, Christoph Plass, PhD, Lars Bullinger, MD, PhD, Rainer Claus, MD

Blood (2013) 122 (21): 2539.

https://doi.org/10.1182/blood.V122.21.2539.2539

Published: 2013

Journal Articles

The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia

Krzysztof Giannopoulos, MD, PhD, Malgorzata Zajac, Anna Dolnik, Stephany Correa, Konstanze Dohner, Richard F. Schlenk, MD, Lars Bullinger, MD, PhD

Blood (2013) 122 (21): 2563.

https://doi.org/10.1182/blood.V122.21.2563.2563

Published: 2013

Journal Articles

Inhibition Of Telomerase Is a Novel and Effective Therapy In MLL-Rearranged Acute Myeloid Leukemia (AML)

Claudia Bruedigam, Frederik Otzen Bagger, MSc, Catherine Paine Kuhn, Therese Vu, Rebecca Austin, Florian H Heidel, MD, Lars Bullinger, MD, PhD, Geoff R Hill, Scott A. Armstrong, MD, PhD, David A. Williams, MD, Steven W Lane, MD, PhD

Blood (2013) 122 (21): 2887.

https://doi.org/10.1182/blood.V122.21.2887.2887

Published: 2013

Journal Articles

Expression Of FLT3-ITD Dysregulates The DBC1-Sirt1-p53 Signaling and Promotes Therapy Resistance

Daniel Sasca, MD, Patricia Haehnel, PhD, Kaml I.K. Khawaja, Birgit Enders, Lars Bullinger, MD, PhD, Matthias Theobald, MD, PhD, Thomas Kindler, MD

Blood (2013) 122 (21): 3789.

https://doi.org/10.1182/blood.V122.21.3789.3789

Published: 2013

Journal Articles

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Vanessa Schneider, Lars Bullinger, MD, PhD, Lu Zhang, Markus Rojewski, Markus Wiesneth, Susanne Hofmann, Marlies Goetz, Hubert Schrezenmeier, MD, Ulla Botzenhardt, Thomas F.E. Barth, Konstanze Doehner, MD, Hartmut Doehner, MD, Jochen Greiner, MD

Blood (2013) 122 (21): 2624.

https://doi.org/10.1182/blood.V122.21.2624.2624

Published: 2013

Journal Articles

Improving The Analysis Of Gene Expression Profiles By Comparing AML Blasts With Their Nearest Normal Counterparts

Nicolas Rapin, PhD, Frederik Otzen Bagger, MSc, Johan Jendholm, PhD, Helena Isabel Mora-Jensen, Msc, Anders Krogh, PhD, Alexander Kohlmann, PhD, Christian Thiede, MD, Niels Borregaard, MD, PhD, Lars Bullinger, MD, PhD, Ole Winther, PhD, Kim Theilgaard-Mönch, MD, PhD, Bo Porse, PhD

Blood (2013) 122 (21): 2568.

https://doi.org/10.1182/blood.V122.21.2568.2568

Published: 2013

Journal Articles

Development Of a 47 Gene Sequencing Panel For Common Mutations Present In Multiple Myeloma : Preliminary Results In 77 p53 Deleted Patients

K. Martin Kortuem, MD, Christian Langer, MD, Esteban Braggio, Ph.D., Scott Van Wier, Jan Egan, PhD, Laura Bruins, Jessica Schmidt, Lars Bullinger, MD, PhD, Miriam Kull, MD, Stefan Knop, MD, Hermann Einsele, MD, A. Keith Stewart, MBA, MB, CHB

Blood (2013) 122 (21): 4449.

https://doi.org/10.1182/blood.V122.21.4449.4449

Published: 2013

Journal Articles

Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG)

Blood (2013) 122 (21): 1332.

https://doi.org/10.1182/blood.V122.21.1332.1332

Published: 2013

Journal Articles

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Kiran Tawana, MD, Aline Renneville, Jun Wang, PhD, Panayiotis Georgiades, Xavier Thomas, MD, Valerie Mialou, MD, Aleksander Savic, MD, Frederik W Van Delft, MD PhD, Jennifer G. Treleaven, MD, Sameena Iqbal, Norio Asou, MD, PhD, Naokuni Uike, MD, Konstanze Döhner, MD, Lars Bullinger, MD, PhD, Matthias Stelljes, MD, Csaba Bödör, PhD, James D. Cavenagh, MD, Doris Steinemann, PhD, Tim Ripperger, MD, Brigitte Schlegelberger, MD, PhD, Peter Vandenberghe, MD, PhD, Anne Uyttebroeck, MD, Josep F. Nomdedeu, MD, Henrik Hjorth-Hansen, MD, PhD, Rosemary E Gale, PhD, Cynthia L. Toze, MD, FRCP(C), Michael J. Barnett, BMBS, FRCPC, FRCP, FRCPath, Marianna Zombori, MD, Krisztian Kallay, MD, Jiri Pavlu, MD, Pim Mutsaers, MD, Fred H Menko, MD, Angela Thomas, PhD, FRCPath, FRCP, MB, BS, Christine Wright, MD, Jessica Okosun, MD, Chey Loveday, PhD, Pierre Fenaux, MD, PhD, Hamish Scott, PhD, Claude Preudhomme, Claude Chelala, PhD, Alison Male, MD, Carolyn J. Owen, MD, FRCPC, Matthew Smith, MD, PhD, Jude Fitzgibbon, PhD

Blood (2013) 122 (21): 740.

https://doi.org/10.1182/blood.V122.21.740.740

Published: 2013

Journal Articles

Distinct Biological and Transcriptional Features Of FLT3-ITD Variants In Vitro and In Vivo

Patricia Arreba-Tutusaus, M.Sc, Lars Bullinger, MD, PhD, Anja Polanetzki, Tina M Schnoeder, PhD, Raghavan V. Thangapandi, M.Sc., Konstanze Döhner, MD, Thomas Fischer, M.D. Ph.D., Florian H Heidel, MD

Blood (2013) 122 (21): 481.

https://doi.org/10.1182/blood.V122.21.481.481

Published: 2013

Journal Articles

Epo-Induced Erythroid Maturation Is Dependent On Plcγ1 Signalling

Tina M Schnoeder, PhD, Patricia Arreba-Tutusaus, MSc, Inga Griehl, cand. med., Lars Bullinger, MD, PhD, Konstanze Doehner, MD, Christoph Plass, PhD, Daniel B Lipka, MD, Florian H Heidel, MD, Thomas Fischer, M.D. Ph.D.

Blood (2013) 122 (21): 1182.

https://doi.org/10.1182/blood.V122.21.1182.1182

Published: 2013

NARROW

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

The Oligodendrocyte Lineage Transcription Factor 2 (OLIG2) Is Epigenetically Regulated in AML and Suppresses Leukemia Cell Growth

ABCB1 Expression in Acute Myeloid Leukemia (AML): A Possible Predictive Value for Treatment Resistance?

Cytotoxic T-Lymphocytes Recognize and Target Leukemic Stem Cells

Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories

Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)

Constitutive gp130-JAK-STAT3 Signaling Induces a Plasma Cell Disorder Representing Genetic and Clinical Features of Human Myeloma – a Novel in Vivo Model for the Patient Subgroup Characterized By a STAT3 Target Gene Signature

Lenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q)

Decitabine Response Associated Gene Expression Patterns In Acute Myeloid Leukemia (AML)

Differential DNA Methylation Predicts Response To Combined Treatment Regimens With a DNA Methyltransferase Inhibitor In Acute Myeloid Leukemia (AML)

The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia

Inhibition Of Telomerase Is a Novel and Effective Therapy In MLL-Rearranged Acute Myeloid Leukemia (AML)

Expression Of FLT3-ITD Dysregulates The DBC1-Sirt1-p53 Signaling and Promotes Therapy Resistance

Analysis Of Leukemic Stem Cell Population Comparing NPM1 wt and NPM1 mut AML Patients and Potential Therapeutic Targets

Improving The Analysis Of Gene Expression Profiles By Comparing AML Blasts With Their Nearest Normal Counterparts

Development Of a 47 Gene Sequencing Panel For Common Mutations Present In Multiple Myeloma : Preliminary Results In 77 p53 Deleted Patients

Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG)

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Distinct Biological and Transcriptional Features Of FLT3-ITD Variants In Vitro and In Vivo

Epo-Induced Erythroid Maturation Is Dependent On Plcγ1 Signalling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only